No, it decreases it
Just took the test - correct answer is 'B' ; Increase Urine Output
to decrease the intracranial pressure
Mannitol
draining of csf, hyperosmotic agent like mannitol, or diureticcraniectomy
Increased intracranial pressure can lead to changes in blood pressure due to the body's compensatory mechanisms. Typically, there is an initial increase in blood pressure in response to increased intracranial pressure to maintain cerebral perfusion. However, as intracranial pressure continues to rise, blood pressure may decrease due to impaired cerebral autoregulation and compromised blood flow to the brain. Overall, the relationship between intracranial pressure and blood pressure is complex and can vary depending on individual factors and the underlying cause of increased intracranial pressure.
Yes, mannitol can cause cells to crenate, particularly red blood cells. Mannitol is a hypertonic solution, meaning it has a higher solute concentration than the fluid inside the cells. When cells are exposed to mannitol, water moves out of the cells to balance the solute concentrations, leading to cell shrinkage or crenation. This effect is typically seen in situations where mannitol is used therapeutically, such as in reducing intracranial pressure.
provide complete bed rest without toilet privilege, positioning, position patient in semi Fowler's position and giving Mannitol as prescribed by the doctor.
Raised intracranial pressure is a relatively common problem facing the clinician treating neurocritically ill patients. It is a leading cause of death in patients with intracranial pathology. There is a lack of controlled clinical trials evaluating most of the therapies currently available for raised intracranial pressure. The basic pathophysiologic and clinical principles of raised intracranial pressure are discussed and the major treatment options are presented. Patients with raised intracranial pressure should be evaluated immediately with particular attention to airway and hemodynamic status. Controlled hyperventilation and hyperosmolality (using mannitol or hypertonic saline solutions) frequently are administered simultaneously. In patients with refractory elevation of intracranial pressure other therapies such as barbiturate coma and surgical interventions are available....so, NOPE!
A sign of the effectiveness of IV mannitol is a decrease in intracranial pressure (ICP), which can be assessed through clinical symptoms such as improved neurological status, reduced headache, or decreased levels of consciousness. Additionally, monitoring for increased urine output is also indicative of mannitol's osmotic diuretic effect, suggesting that the drug is functioning as intended to reduce cerebral edema.
Mannitol is given to raise blood pressure during hemodialysis
Mannitol is a hyperosmotic agent often used to reduce intracranial pressure and may be administered to stroke patients. However, caution is needed in diabetic patients, as mannitol can lead to fluctuations in blood glucose levels. It's essential to monitor the patient's glucose closely and consider the overall clinical picture before administration. Consulting with a healthcare professional is crucial for individualized treatment decisions.
Increased intracranial pressure can be caused by various factors such as traumatic brain injury, brain tumors, hydrocephalus, cerebral edema, meningitis, and intracranial hemorrhage. Additionally, conditions like dehydration, obstructed cerebrospinal fluid flow, or certain medications can also contribute to elevated intracranial pressure.